<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01786954</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00036498</org_study_id>
    <nct_id>NCT01786954</nct_id>
  </id_info>
  <brief_title>iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery</brief_title>
  <official_title>A Comparative Study of Icare Rebound Tonometry With Other Tonometry Modalities in Patients Following Vitreoretinal Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the measurement of pressure inside the eye using three
      different FDA-approved devices (Icare, Tonopen, and Goldmann applanation).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The three above devices will be used to measure intraocular pressure in patients one day
      following vitreoretinal surgery. The underlying reason for surgery is not being considered in
      this study. The measured pressures will be compared across devices in eyes filled with fluid,
      gas, and silicone oil.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Intraocular Pressure</measure>
    <time_frame>postoperative day #1</time_frame>
    <description>The primary outcome is the measurement of intraocular pressure on postoperative day #1 following vitreoretinal surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>postoperative day #1</time_frame>
    <description>The secondary outcome is the onset of any adverse events related to measurement of intraocular pressure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Icare then Goldmann then Tonopen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Goldmann then Tonopen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Icare then Tonopen then Goldmann</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation. Patients receive Icare first and then are randomized to receive Tonopen followed by Goldmann OR Goldmann followed by Tonopen. This arm is Icare then Tonopen then Goldmann.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Icare rebound tonometry</intervention_name>
    <arm_group_label>Icare then Goldmann then Tonopen</arm_group_label>
    <arm_group_label>Icare then Tonopen then Goldmann</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tonopen applanation</intervention_name>
    <arm_group_label>Icare then Goldmann then Tonopen</arm_group_label>
    <arm_group_label>Icare then Tonopen then Goldmann</arm_group_label>
    <other_name>Tonopen Avia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Goldmann applanation</intervention_name>
    <arm_group_label>Icare then Goldmann then Tonopen</arm_group_label>
    <arm_group_label>Icare then Tonopen then Goldmann</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Duke Eye Center patients 18 years or older

          -  capacity to give legally effective consent

          -  scheduled to undergo vitreoretinal surgery

        Exclusion Criteria:

          -  individuals unable to give consent

          -  minors
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Hahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Eye Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2013</study_first_submitted>
  <study_first_submitted_qc>February 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2013</study_first_posted>
  <results_first_submitted>January 20, 2016</results_first_submitted>
  <results_first_submitted_qc>January 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 22, 2016</results_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vitreoretinal surgery</keyword>
  <keyword>intraocular pressure</keyword>
  <keyword>applanation</keyword>
  <keyword>rebound</keyword>
  <keyword>tonometry</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1: Icare Then Goldmann Then Tonopen</title>
          <description>Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry then Goldmann applanation then Tonopen applanation.
Icare rebound tonometry
Goldmann applanation
Tonopen applanation</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2: Icare Then Tonopen Then Goldmann</title>
          <description>Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry then Tonopen applanation then Goldmann applanation.
Icare rebound tonometry
Tonopen applanation
Goldmann applanation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Icare, Goldmann, Tonopen</title>
          <description>Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation.
Icare rebound tonometry
Tonopen applanation
Goldmann applanation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Intraocular Pressure</title>
        <description>The primary outcome is the measurement of intraocular pressure on postoperative day #1 following vitreoretinal surgery.</description>
        <time_frame>postoperative day #1</time_frame>
        <population>Of the 68 patients enrolled, only 50 patients who received IOP measurement one day following vitrectomy surgery were analyzed. Those with IOP measurement following non-vitrectomy surgery were subsequently excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Icare</title>
            <description>Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation.
Icare rebound tonometry</description>
          </group>
          <group group_id="O2">
            <title>Tonopen</title>
            <description>Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation.</description>
          </group>
          <group group_id="O3">
            <title>Goldmann</title>
            <description>Enrolled patients will be subjected to intraocular pressure measurement using Icare rebound tonometry, Tonopen applanation, and Goldmann applanation.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Intraocular Pressure</title>
          <description>The primary outcome is the measurement of intraocular pressure on postoperative day #1 following vitreoretinal surgery.</description>
          <population>Of the 68 patients enrolled, only 50 patients who received IOP measurement one day following vitrectomy surgery were analyzed. Those with IOP measurement following non-vitrectomy surgery were subsequently excluded from the analysis.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.9" spread="8.9"/>
                    <measurement group_id="O2" value="16.0" spread="7.3"/>
                    <measurement group_id="O3" value="16.9" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>The secondary outcome is the onset of any adverse events related to measurement of intraocular pressure.</description>
        <time_frame>postoperative day #1</time_frame>
        <population>Adverse events were analyzed for all enrolled patients, in contrast to IOP measurements, which were only analyzed for the 50 post-vitrectomy patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Icare</title>
          </group>
          <group group_id="O2">
            <title>Tonopen</title>
          </group>
          <group group_id="O3">
            <title>Goldmann</title>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>The secondary outcome is the onset of any adverse events related to measurement of intraocular pressure.</description>
          <population>Adverse events were analyzed for all enrolled patients, in contrast to IOP measurements, which were only analyzed for the 50 post-vitrectomy patients.</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <desc>All patients were examined with a complete ophthalmic exam following IOP measurements.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sequence 1: Icare, Goldmann, Tonopen</title>
          <description>Sequence 1: Icare, then Goldmann, then Tonopen</description>
        </group>
        <group group_id="E2">
          <title>Sequence 2: Icare, Tonopen, Goldmann</title>
          <description>Sequence 2: Icare, then Tonopen, then Goldmann</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Paul Hahn</name_or_title>
      <organization>Duke Eye Center</organization>
      <phone>919-684-5631</phone>
      <email>paul.s.hahn@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

